CBR-5884

• Description:

  CBR-5884 is an active, selective inhibitor of phosphoglycerate dehydrogenase (PHGDH) with an IC50 of 33 μM. CBR-5884 inhibits de novo serine synthesis in cancer cells and is selectively toxic to cancer cell lines with high serine biosynthetic activity. CBR-5884 selectively inhibits the proliferation of melanoma and breast cancer lines that have a high propensity for serine synthesis[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H335

• Target:

  Phosphoglycerate Dehydrogenase (PHGDH)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/CBR-5884.html

• Concentration:

  10mM

• Purity:

  99.02

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=C(C)C(SC#N)=C(NC(C2=CC=CO2)=O)S1)OCC

• Molecular Formula:

  C14H12N2O4S2

• Molecular Weight:

  336.39

• Precautions:

  H315, H319, H335

• References & Citations:

  [1]Edouard Mullarky et al. Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers Proc Natl Acad Sci U S A, 2016 Feb 16, 113 (7) :1778-83.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [681159-27-3]